Feedback / Questions
Gavreto (pralsetinib) - Rigel Pharmaceuticals
Gavreto: Newly added patent in Orange Book
(Orange Book)
-
Mar 6, 2026 -
Expiry on Jul 7, 2042
Patent
•
Endocrine Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • Thyroid Gland Carcinoma
https://www.accessdata.fda.gov/scripts/cder/ob/search_patent.cfm?listed=new
Mar 6, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious